Taiwan · Delayed Price · Currency is TWD RBC Bioscience Statistics
Total Valuation
RBC Bioscience has a market cap or net worth of TWD 210.86 million. The enterprise value is 586.46 million.
| Market Cap | 210.86M |
| Enterprise Value | 586.46M |
Important Dates
The next estimated earnings date is Tuesday, April 21, 2026.
| Earnings Date | Apr 21, 2026 |
| Ex-Dividend Date | Oct 2, 2025 |
Share Statistics
RBC Bioscience has 12.98 million shares outstanding. The number of shares has increased by 0.34% in one year.
| Current Share Class | 12.98M |
| Shares Outstanding | 12.98M |
| Shares Change (YoY) | +0.34% |
| Shares Change (QoQ) | -0.26% |
| Owned by Insiders (%) | 32.40% |
| Owned by Institutions (%) | n/a |
| Float | 6.72M |
Valuation Ratios
The trailing PE ratio is 11.91.
| PE Ratio | 11.91 |
| Forward PE | n/a |
| PS Ratio | 1.04 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | 6.85 |
| P/OCF Ratio | 5.48 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.95, with an EV/FCF ratio of 19.04.
| EV / Earnings | 29.94 |
| EV / Sales | 2.91 |
| EV / EBITDA | 11.95 |
| EV / EBIT | 17.81 |
| EV / FCF | 19.04 |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 1.68.
| Current Ratio | 1.29 |
| Quick Ratio | 0.77 |
| Debt / Equity | 1.68 |
| Debt / EBITDA | 8.89 |
| Debt / FCF | 14.17 |
| Interest Coverage | 3.24 |
Financial Efficiency
Return on equity (ROE) is 7.70% and return on invested capital (ROIC) is 4.07%.
| Return on Equity (ROE) | 7.70% |
| Return on Assets (ROA) | 2.69% |
| Return on Invested Capital (ROIC) | 4.07% |
| Return on Capital Employed (ROCE) | 5.14% |
| Weighted Average Cost of Capital (WACC) | 2.80% |
| Revenue Per Employee | 3.88M |
| Profits Per Employee | 376,750 |
| Employee Count | 52 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, RBC Bioscience has paid 5.31 million in taxes.
| Income Tax | 5.31M |
| Effective Tax Rate | 21.33% |
Stock Price Statistics
The stock price has decreased by -13.23% in the last 52 weeks. The beta is 0.10, so RBC Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -13.23% |
| 50-Day Moving Average | 16.71 |
| 200-Day Moving Average | 17.16 |
| Relative Strength Index (RSI) | 43.44 |
| Average Volume (20 Days) | 16,582 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RBC Bioscience had revenue of TWD 201.85 million and earned 19.59 million in profits. Earnings per share was 1.36.
| Revenue | 201.85M |
| Gross Profit | 96.94M |
| Operating Income | 32.93M |
| Pretax Income | 24.90M |
| Net Income | 19.59M |
| EBITDA | 47.88M |
| EBIT | 32.93M |
| Earnings Per Share (EPS) | 1.36 |
Balance Sheet
The company has 60.98 million in cash and 436.59 million in debt, with a net cash position of -375.60 million or -28.95 per share.
| Cash & Cash Equivalents | 60.98M |
| Total Debt | 436.59M |
| Net Cash | -375.60M |
| Net Cash Per Share | -28.95 |
| Equity (Book Value) | 260.47M |
| Book Value Per Share | 18.25 |
| Working Capital | 33.27M |
Cash Flow
In the last 12 months, operating cash flow was 38.45 million and capital expenditures -7.65 million, giving a free cash flow of 30.80 million.
| Operating Cash Flow | 38.45M |
| Capital Expenditures | -7.65M |
| Free Cash Flow | 30.80M |
| FCF Per Share | 2.37 |
Margins
Gross margin is 48.03%, with operating and profit margins of 16.31% and 9.71%.
| Gross Margin | 48.03% |
| Operating Margin | 16.31% |
| Pretax Margin | 12.34% |
| Profit Margin | 9.71% |
| EBITDA Margin | 23.72% |
| EBIT Margin | 16.31% |
| FCF Margin | 15.26% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 1.85%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 1.85% |
| Dividend Growth (YoY) | -67.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 66.23% |
| Buyback Yield | -0.34% |
| Shareholder Yield | 1.51% |
| Earnings Yield | 9.29% |
| FCF Yield | 14.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 11, 2025. It was a forward split with a ratio of 1.1.
| Last Split Date | Aug 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
RBC Bioscience has an Altman Z-Score of 0.89 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.89 |
| Piotroski F-Score | 6 |